Atossa Therapeutics Valuation
Is ATOS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ATOS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ATOS * (MX$28.1) is trading below our estimate of fair value (MX$1480.34)
Significantly Below Fair Value: ATOS * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ATOS *?
Other financial metrics that can be useful for relative valuation.
| What is ATOS *'s n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$208.00m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -3.8x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ATOS *'s PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.9x | ||
LAB B Genomma Lab Internacional. de | 1.6x | 26.7% | Mex$15.5b |
ALSEN Sensorion | 5.8x | 42.8% | €193.4m |
2181 Mabpharm | 7.4x | n/a | HK$1.6b |
ABOS Acumen Pharmaceuticals | 0.8x | -13.5% | US$209.7m |
ATOS * Atossa Therapeutics | 2.3x | 63.9% | Mex$208.0m |
Price-To-Book vs Peers: ATOS * is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (3.9x).
Price to Earnings Ratio vs Industry
How does ATOS *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Book vs Industry: ATOS * is good value based on its Price-To-Book Ratio (2.3x) compared to the Global Biotechs industry average (2.5x).
Price to Book Ratio vs Fair Ratio
What is ATOS *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.3x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate ATOS *'s Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$28.10 | Mex$79.42 +182.6% | 20.2% | Mex$102.11 | Mex$68.07 | n/a | 3 |
| Apr ’25 | Mex$33.47 | Mex$78.25 +133.8% | 18.0% | Mex$98.17 | Mex$68.29 | n/a | 3 |
| Mar ’25 | Mex$18.00 | Mex$78.25 +334.7% | 18.0% | Mex$98.17 | Mex$68.29 | n/a | 3 |
| Feb ’25 | Mex$15.00 | Mex$82.82 +452.1% | 17.9% | Mex$97.68 | Mex$67.95 | n/a | 2 |
| Jan ’25 | Mex$14.41 | Mex$82.82 +474.7% | 17.9% | Mex$97.68 | Mex$67.95 | n/a | 2 |
| Dec ’24 | Mex$13.00 | Mex$82.42 +534.0% | 15.8% | Mex$95.43 | Mex$69.41 | n/a | 2 |
| Nov ’24 | Mex$12.50 | Mex$85.13 +581.0% | 12.9% | Mex$96.87 | Mex$70.45 | n/a | 3 |
| Oct ’24 | Mex$14.00 | Mex$85.13 +508.1% | 12.9% | Mex$96.87 | Mex$70.45 | n/a | 3 |
| Sep ’24 | Mex$14.00 | Mex$83.15 +493.9% | 13.5% | Mex$94.38 | Mex$71.91 | n/a | 2 |
| Aug ’24 | Mex$19.00 | Mex$83.15 +337.6% | 13.5% | Mex$94.38 | Mex$71.91 | n/a | 2 |
| Jul ’24 | Mex$21.74 | Mex$83.15 +282.5% | 13.5% | Mex$94.38 | Mex$71.91 | n/a | 2 |
| Jun ’24 | Mex$16.50 | Mex$83.15 +403.9% | 13.5% | Mex$94.38 | Mex$71.91 | n/a | 2 |
| May ’24 | Mex$11.95 | Mex$86.58 +624.5% | 15.8% | Mex$100.25 | Mex$72.91 | Mex$26.25 | 2 |
| Apr ’24 | Mex$12.80 | Mex$86.58 +576.4% | 15.8% | Mex$100.25 | Mex$72.91 | Mex$33.47 | 2 |
| Mar ’24 | Mex$14.25 | Mex$91.83 +544.4% | 20.0% | Mex$110.19 | Mex$73.46 | Mex$18.00 | 2 |
| Feb ’24 | Mex$16.00 | Mex$97.50 +509.4% | 20.0% | Mex$117.00 | Mex$78.00 | Mex$15.00 | 2 |
| Jan ’24 | Mex$10.21 | Mex$97.50 +855.0% | 20.0% | Mex$117.00 | Mex$78.00 | Mex$14.41 | 2 |
| Dec ’23 | Mex$14.00 | Mex$97.50 +596.5% | 20.0% | Mex$117.00 | Mex$78.00 | Mex$13.00 | 2 |
| Nov ’23 | Mex$19.00 | Mex$109.93 +478.6% | 27.3% | Mex$139.91 | Mex$79.95 | Mex$12.50 | 2 |
| Oct ’23 | Mex$16.70 | Mex$109.93 +558.3% | 27.3% | Mex$139.91 | Mex$79.95 | Mex$14.00 | 2 |
| Sep ’23 | Mex$18.80 | Mex$109.93 +484.7% | 27.3% | Mex$139.91 | Mex$79.95 | Mex$14.00 | 2 |
| Aug ’23 | Mex$19.10 | Mex$116.76 +511.3% | 30.4% | Mex$152.30 | Mex$81.23 | Mex$19.00 | 2 |
| Jul ’23 | Mex$19.96 | Mex$112.41 +463.2% | 30.4% | Mex$146.62 | Mex$78.20 | Mex$21.74 | 2 |
| Jun ’23 | Mex$18.88 | Mex$112.41 +495.4% | 30.4% | Mex$146.62 | Mex$78.20 | Mex$16.50 | 2 |
| May ’23 | Mex$20.64 | Mex$123.94 +500.5% | 33.3% | Mex$165.25 | Mex$82.63 | Mex$11.95 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.